Cargando…
TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma
Autores principales: | Gordon, Max J., Bond, David A., Kittai, Adam S., Amirmokhtari, Neda, Steinbrunner, Abigail, Huffman, Allison, Orellana-Noia, Victor, Shouse, Geoffrey, Cohen, Jonathon B., Phillips, Tycel, Danilov, Alexey V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620592/ https://www.ncbi.nlm.nih.gov/pubmed/37226703 http://dx.doi.org/10.3324/haematol.2023.283074 |
Ejemplares similares
-
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023) -
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
por: Shouse, Geoffrey, et al.
Publicado: (2023) -
Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy
por: Girard, Jennifer, et al.
Publicado: (2019) -
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma
por: Thieme, Elana, et al.
Publicado: (2022) -
P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL
por: Phillips, Tycel, et al.
Publicado: (2023)